---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-341206"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2026-08-10T11:05:20+00:00"
generated_at: "2026-08-10T11:10:22.019388+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome Q2 2026 revenue up 46% to $218.4M; AUVELITY Alzheimer's launch underway

## Summary
- Total net product revenue $218.4M, +46% YoY; AUVELITY sales $180.3M (+51% YoY), SUNOSI $35.8M (+20%), SYMBRAVO $2.3M (+461%).
- Net loss $51.3M ($0.99/share) vs $48.0M loss ($0.97) in Q2 2025; SG&A up to $208.1M from $130.3M on launch activities.
- AUVELITY launched for Alzheimer's disease agitation in June 2026; new-to-brand Rx +126% in patients ≥65 in first 8 weeks.
- NDA for AXS-12 (cataplexy in narcolepsy) accepted by FDA; PDUFA target action date May 1, 2027.
- Cash $319.9M at June 30, 2026; guidance says sufficient to fund operations into cash flow positivity.

## SEC filing metadata
- accession: 0001193125-26-341206
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2026-08-10T11:05:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/0001193125-26-341206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000119312526341206/axsm-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-341206
- JSON: https://secwatch.observer/filing/0001193125-26-341206.json
- Plain text: https://secwatch.observer/filing/0001193125-26-341206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.